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Abstract The following review summarizes the progress
in multiple sclerosis research published in the Journal of
Neurology in 2009.
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Introduction
Multiple sclerosis is a chronic demyelinating neuroin-
ﬂammatory disease of the central nervous system of
unknown etiology. Clinical disease usually starts with
recurrent and reversible neurological deﬁcits in early
adulthood and transforms into a disease course with con-
tinuous and progressive neurological decline 20 years later.
Inﬂammation composed of mononuclear cells, breakdown
of the blood brain barrier, focal plaques of demyelination
and axonal damage characterize acute MS lesions and can
be effectively targeted by anti-inﬂammatory therapies. The
progressive disease phase is characterized by a persistent
low-level inﬂammatory response which eludes current
treatment efforts.
Etiology: genetic and environmental factors
Multiple sclerosis is most likely caused by a complex
interplay between polygenetic and environmental factors.
Genetic susceptibility to multiple sclerosis is associated
with a number of immunologically relevant genes, partic-
ularly with the HLA DR15 haplotype in Caucasians.
Fernandez et al. [5] studied HLA class II alleles in patients
with multiple sclerosis in the Biscay province of northern
Spain. They identiﬁed the HLA class II allele DQB1*0602
as a potentially predisposing allele in their study popula-
tion. The haplotype DRB1*0101 had a signiﬁcantly lower
frequency in the MS group.
The inﬂammatory inﬁltrate of MS consists mainly of
mononuclear cells which are located around small veins,
but which also can inﬁltrate white and to a lesser extent
grey matter. Migration of inﬂammatory cells from the
blood stream to the CNS requires the interaction of adhe-
sion molecules, including the family of selectins. Fenoglio
et al. [4] studied single nucleotide polymorphisms of the
selectin gene cluster in MS patients and controls of Cau-
casian origin, but no inﬂuence on disease susceptibility was
observed.
Environmental factors currently implicated in the path-
ogenesis of MS include viral infections, vitamin D deﬁ-
ciency and smoking. Vitamin D, which is converted in its
active form by sunlight exposure to the skin, is an immune-
modulator and vitamin D supplementation has a protective
effect. Current knowledge about hypovitaminosis D as an
environmental risk factor for MS has been thoroughly
summarized by Pierrot-Deseilligny [16]. Although sunlight
exposure and vitamin D levels are diminished in a signif-
icant number of the inhabitants of Alaska, Wallin et al. [22]
found a low MS prevalence in this area.
Clinical presentation
Many patients who later develop MS present ﬁrst with a
clinically isolated syndrome, which is usually categorized
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symptoms was associated with a decreased risk for the
development of clinically deﬁnite MS. Clinical predictors
of early second demyelinating events were identiﬁed in a
study from the UCSF MS Center [15]. These included
younger age at presentation, non-white ethnicity and a
lower number of affected functional systems. Analysing
data obtained in the national German MS Registry, Stuke
[18] report sensory problems, paresis and visual dysfunc-
tion as the most frequently reported initial MS symptoms.
Fatigue, bladder dysfunction, spasticity and ataxia became
eminent with longer disease duration.
Using a questionnaire approach in 18 different European
countries, Messmer [13] describes the factors which
inﬂuence the employment status of people with multiple
sclerosis. Symptoms associated with a negative impact on
employment were mobility problems, visual impairment
and memory problems. Fatigue, previously described as
important for the decision to leave work, did not reach
signiﬁcance in this study. Financial aspects and workplace
parameters such as accessibility and ﬂexible work sched-
ules were signiﬁcant factors for staying employed.
The inﬂuence of the lifestyle factor smoking on disease
progression in multiple sclerosis was studied in a prospec-
tive population based study in Tasmania [17]. Smoking was
positively associated with clinical disability progression
over a 3-year observation period.
Natural history studies of MS previously revealed
many similarities between patients suffering from primary
progressive disease (PPMS) and patients who reached a
secondary progressive disease course (SPMS) after an
initial relapsing remitting one. Comparing PPMS with
SPMS in a Canadian MS study population, Tremlett et al.
[20] report that SPMS patients enter the progressive
disease phase at a later age than primary progressive
patients.
Paraclinical parameters
The diagnosis of MS requires the dissemination of the
disease in time and space. This can be documented on
clinical grounds or by paraclinical and laboratory param-
eters. Magnetic resonance imaging (MRI), cerebrospinal
ﬂuid (CSF) and electrophysiological studies contribute
considerably to an early and deﬁnitive MS diagnosis.
Oligoclonal band-negative and -positive patients were
studied by Huttner et al. [8] with respect to the fulﬁlment of
Barkhof’s diagnostic MRI criteria for MS. The two patient
groups did not differ in overall fulﬁlment of these criteria,
but OCB-negative patients had signiﬁcantly more juxta-
cortical lesions and fewer infratentorial lesions than
OCB-positive patients.
Applying quantitative MRI measurements such as
magnetization transfer ratio (MTR) to a group of secondary
progressive MS patients, signiﬁcant correlations were
obtained between multiple sclerosis functional composite
scores (MSFC) and MTR values in normal appearing white
matter (NAWM), lesions and grey matter. Grey matter
MTR values emerged as the best predictors of MSFC
scores [6]. Signiﬁcant correlations between MRI MTR
measures and EDSS were not found. These, however,
could be obtained for transcranial magnetic stimulation
(TMS) measurements and EDSS in a study by Conte et al.
[3].
Extensive studies with CSF and serum samples of MS
patients and controls have not established a speciﬁc and
sensitive diagnostic biomarker for this disease. In this
respect, Massa et al. [11] also failed to establish the serum
urate concentration as a strong predictor of MS risk in a
prospective study.
Neuromyelitis optica
Neuromyelitis optica (NMO) was once considered to be an
uncommon variant of MS, but is regarded now as a disease
in its own right. In a population-based study in the multi-
ethnic population of Cuba, NMO prevalence was 0.52/
100000 with no difference by ethnicity [2]. Antibodies
against the water channel protein aquaporin-4 (AQP-4) are
relatively speciﬁc for this disease and useful to distinguish
NMO from MS. Interleukin-6, which is elevated in the CSF
of NMO patients but not in the CSF of MS patients, might
be another potential biomarker to differentiate these
demyelinating disorders [21]. Atypical or limited clinical
variants of neuromyelitis optica have been deﬁned by the
presence of AQP-4 antibodies in a number of patients
presenting with inﬂammatory CNS disease in a retrospec-
tive study in Tuscany [1].
Therapy
The current MS therapy is based on immunomodulatory
drugs such as interferon-beta and glatiramer acetate,
immunosuppressive therapies such as mitoxantrone and
biologics such as natalizumab, which target speciﬁc mol-
ecules on the cell surface of immune cells. Treatment
involves also the management of MS symptoms.
Drugs work only if patients take them, and patient
adherence to therapy is a relevant clinical problem in many
chronic diseases. Treatment adherence to injected disease-
modifying therapies in MS was investigated in a multi-
center observational study by Treadaway et al. [19], which
reported that the non-adherence rate was in the range of
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12336–39%. The most often reported reason for missing
injections was that patients simply forgot to administer
them. Older age at diagnosis and no prior disease-modi-
fying therapy favoured adherence.
Hutchinson et al. [7] studied the efﬁcacy of natalizumab
therapy in subgroups of AFFIRM and SENTINEL which
included prior treatment-naive MS patients with highly
active relapsing MS (AFFIRM) or highly active disease
despite interferon-ß treatment (SENTINEL). Highly active
MS was deﬁned as C2 relapses/year prior to study entry and
C1G d ? lesion on T1 weighted MRI at study entry. Natal-
izumab reduced the annualized relapse rate by 81% in the
AFFIRM and 76% in the SENTINEL trial and the risk of
disability progression by 64% in the former and 58% in the
latter study, demonstrating efﬁcacy also in highly active
disease.
Serious adverse events in MS therapy have become
increasingly eminent with approved monoclonal antibody
therapies for highly active relapsing remitting disease.
Johnson et al. [9] analyzed the willingness of MS patients
to accept potential life-threatening adverse events in
exchange for therapeutic beneﬁts. They found that MS
patients were willing to accept serious adverse events
(SAE), such as death or disability from progressive mul-
tifocal leukoencephalopathy, at an annual risk of 0.38% in
return for a decrease in relapse rate and disease progres-
sion. In fact, the mean maximum acceptable annual risk of
SAE patients are willing to accept is higher than the
observed risk for currently marketed therapies.
Teriﬂunomide is one of a number of oral MS therapeutics
being tested in phase III clinical trials at the moment.
Merrill et al. [12] tested the efﬁcacy of this anti-inﬂam-
matory drug, which targets a mitochondrial enzyme
important for the de novo pyrimidine synthesis, in a chronic
relapsing animal model for MS. Teriﬂunomide adminis-
tered to DA rats at disease onset or at the onset of remission
prompted a more rapid recovery or reduced the severity of a
clinical relapse, respectively. Clinical improvements were
accompanied by fewer inﬂammatory inﬁltrates and less
demyelination and axonal damage in histopathology.
Neuropsychological deﬁcits in MS include impairments
in both processing speed and memory and affect 40–60%
of patients. In a placebo-controlled double-blind trial by
Morrow et al. [14], patients with cognitive dysfunctions
were randomized to L-amphetamine sulfate or placebo at a
2:1 ratio. No signiﬁcant differences were observed in the
subjective rating of cognition or in measured processing
speed, which were the primary functions tested in the
study. However, cognitively impaired MS patients on
L-amphetamine signiﬁcantly improved on auditory/verbal
and visual/spatial memory tests.
Fatigue is one of the most frequent symptoms in patients
with MS and a considerable number of MS patients
consider fatigue to be their most serious symptom. Treat-
ment options include various medications such as modaﬁ-
nil, as well as non-pharmacological interventions. The
effect of modaﬁnil treatment on fatigue was studied by
Lange et al. [10] in a double-blind placebo-controlled
study. Modaﬁnil treatment reduced fatigue, improved
focused attention and also enhanced ﬁne motoric perfor-
mances and cognitive tasks in their study.
Summary and outlook
Although the etiology of multiple sclerosis remains elusive,
substantial progress has been made in the treatment of the
inﬂammatory component of this disease. Upcoming new
therapies, which include oral medications, will further
broaden the therapeutic repertoire and will emphasize the
importance of weighing treatment beneﬁts against potential
risks.
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